Ecoland International, Inc. (ECIT) awarded new contract, shares rise

Shares of Ecoland International, Inc. (OTCBB: ECIT) climbed 16 percent on Moncontract from Johnson Controls on Monday after the Arizona-based company announced that it was awarded a contract from Johnson Controls (NYSE: JCI) exceeding $1.2 million, to be delivered over the next four months.

ECIT shares touched a high of $0.43 in morning trading on Monday, up from Friday’s closing price of $0.37.

According to a December 5 press release, the newly awarded project “signals the beginning of the second phase of Johnson Controls’ production relocation project,” which Ecoland’s subsidiary, D&R Technology has participated and “played an important role in for the last twelve months.”

The project “demonstrates the success of our business strategy and the confidence of our customer in our ability,” said D&R’s president Drasko Karanovic in the December 5 press release. “It is flattering to be one of the companies that helped Johnson Controls’ achieve best ever financial results for the past year. Our objective for the next period is to maintain and further develop this mutually beneficial relationship. Johnson Controls is world’s market leader in automotive seating with about 45% of the market. We see tremendous potential for our growth by simply satisfying their needs in the global market.”

For the three months ended August 31, Ecoland reported sales of $3,376, and a net loss of $47,730.

In early November, the company announced that it closed the acquisition of D&R Technology, Inc. Pursuant to the share exchange agreement, D&R’s shareholders will receive a majority share ownership in ECIT and it is anticipated that a name change will be made reflecting this change in majority share ownership. Also, according to the share exchange agreement, D&R’s management team will assume operational and managerial control effective immediately, a November 7 press release stated.

D & R Technology Inc. provides engineering, design and the manufacturing of automated tube processing solutions for the automotive industry.

Caduceus Software Systems Corp. (CSOC) soars on pricey marketing campaign

Software medical records management software developer, Caduceus Software Systems Corp. (OTCBB:CSOC) traded more than 16 million shares on Monday, a far cry from the company’s average three-month volume of 49,478 shares, after the onset of a $1 million-plus e-mail campaign spearheaded by VictoryStocks.com.

The campaign was paid for by a third party, listed as “Firdaus Inc.”

The last time Caduceus Software Systems Corp. issued a press release was about a month ago, when the Birmingham, England-based company announced its goals and mission statement.

The Company has the primary goal of providing good valuable medical records management software (MMS) to medical professionals. The Company’s target market is to provide Electronic Health Records (EHR) management for practitioners and physicians, and combine it with the appointment scheduling tools useful for medical office assistants. While some software caters to specifically to doctors and some software caters specifically to their supporting staff, Caduceus MMS integrates these tasks together in a single software solution, the August 16 press release stated.

“The recent news of the American health care reform and the cost of health care in Canada and United States warrant better software to manage the flow of patient information and fast and accurate billing,” sais Derrick Gidden, President of Caduceus Software Systems Corp in the August 16 press release. “The Canadian and American markets are vast and total more than 800,000 private physicians and practitioners. From the news studies, we feel that many of these medical professionals could benefit from our software in terms of our price point, multiple languages, tech support, and platform compatibility requirements.”

For the three months ended June 30, Caduceus Software Systems Corp. reported $0 revenue, and a net loss of $4.9 million.

ACTC moves higher on FDA clearance for stem cell therapy trials

Shares of Advanced Cell Technology, Inc. (OTCBB: ACTC) advanced higher on Thursday following an announcement earlier this week that the U.S. Food and Drug Administration gave the company the green light to conduct clinical trials for a therapy made from embryonic stem cells in patients with Dry Age-Related Macular Degeneration (AMD), a common cause of vision loss.

“Dry AMD is the leading cause of blindness in individuals over the age of 55,” Dr. Robert Lanza, ACTC’s chief scientific officer, said in a statement. “As the population ages, the incidence of AMD is expected to double over the next 20 years, further exacerbating this unmet medical need.”

Age-Related Macular Degeneration has two predominant forms, wet and dry. Dry AMD is the most common form, accounting for almost 90 percent of all cases. The progress of Dry AMD includes a breakdown or thinning of the layer of RPE cells in the patient’s macula, the region at the center of the retina responsible for high acuity vision. Over time, the progressive loss of RPE cells and accompanying loss of photoreceptors can cause severe vision loss and even blindness.

This marks the second FDA approved trial for ACTC’s stem cell product. The first came in November when ACTC received FDA approval for the second human trial of human embryonic stem cells to treat people with Stargardt’s macular dystrophy, a progressive form of blindness.

“ACT is now the first company to receive FDA clearance for two hESC trials, and is now a true translational leader in the field of regenerative medicine,” said Gary Rabin, Interim Chairman and CEO of ACTC in a statement. “It marks a major step forward, not just within the stem cell sector, but, potentially for modern healthcare techniques. We plan to proceed into the clinic with both of our hESC-based programs as quickly as possible.”

Shares of ACTC are up as much as 420 percent over the past three months.

HHWW inches up after big slide

Shares of Horiyoshi Worldwide, Inc. (OTCBB: HHWW) showed signs of life on Thursday after slipping as much as 67 percent from last week’s high of $3.14 earlier this week. Shares rallied almost 8 percent from Wednesday’s closing price in morning trading on Thursday, after the high-end clothing company announced the addition of fashion executive Michelle Stein to its Advisory Board.

A scathing article by Citron Research published last Friday, could’ve played a role in the sharp decline in HHWW’s share price earlier this week.

HHWW is aiming to expand their growth through new categories like Denim and also is looking into getting involved with what’s called “Bridge” or “Complimentary” categories like undergarments (ooh la la), leather goods, footwear, active wear, etc. The company’s near-term  plans for growth call for an expansion of its current collection, solidifying their alliances with key retailers, and appointing a leading management team.

For the quarter ended September 30, 2010 Horiyoshi reported a net loss of $32,476, and no revenue.  HHWW had revenues of $30,633 for the year ended December 31, 2009 and revenues of $153,087 for the six months ended June 30, 2010. As at June 30, 2010 the company had incurred a cumulative net loss of $376,306, had cash of $233,462, and a working capital deficit of $3,690

Shares of HHWW have been up as much as 190 percent over  the past three months, and recently traded for $1.95 per share.